Announced Wed, 19 Aug · 16:55 IST
NephroPlus Q1 FY27: Revenue up 23.7%, EBITDA margin expands 120 bps
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.7%1-day move
₹685.90
prior close
₹698.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.1-3.5-2.9-3.1+0.7—————————
Up moveDown movePending
AI summary
Q1 FY27 revenue grew 23.7% YoY to INR282 crores. Adjusted EBITDA rose 30.7% to INR65 crores, margin expanding 120 bps to 23.1%. Adjusted PAT jumped 41.7% to INR37 crores. Active guests up 13% to 38,262. Network expanded to 550 clinics across 5 countries with 26 new additions. International contributes 45% of revenue. Maintained 15-20% medium-term growth guidance. Saudi first clinic launched, Kazakhstan subsidiary incorporated.
Likely market impact
Strong quarter with 23.7% revenue growth, 120 bps EBITDA margin expansion, and maintained 15-20% medium-term guidance.